Checking the hippo in sarcomatoid renal cell carcinoma with immunotherapy

Joyce K. Hwang; Neeraj Agarwal; James Brugarolas; Tian Zhang

doi:10.1158/1078-0432.CCR-20-3506

Checking the hippo in sarcomatoid renal cell carcinoma with immunotherapy

Joyce K. Hwang, Neeraj Agarwal, James Brugarolas, Tian Zhang

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor–based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.

Original language	English (US)
Pages (from-to)	5-7
Number of pages	3
Journal	Clinical Cancer Research
Volume	27
Issue number	1
DOIs	https://doi.org/10.1158/1078-0432.CCR-20-3506
State	Published - Jan 1 2021

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-20-3506

Cite this

@article{218d763774e441beb6e50b708105e8aa,

title = "Checking the hippo in sarcomatoid renal cell carcinoma with immunotherapy",

abstract = "Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor–based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.",

author = "Hwang, {Joyce K.} and Neeraj Agarwal and James Brugarolas and Tian Zhang",

note = "Funding Information: J. Brugarolas was supported by an NCI SPORE grant (P50 CA196516). Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2021",

month = jan,

day = "1",

doi = "10.1158/1078-0432.CCR-20-3506",

language = "English (US)",

volume = "27",

pages = "5--7",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

TY - JOUR

T1 - Checking the hippo in sarcomatoid renal cell carcinoma with immunotherapy

AU - Hwang, Joyce K.

AU - Agarwal, Neeraj

AU - Brugarolas, James

AU - Zhang, Tian

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor–based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.

AB - Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor–based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85100350763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100350763&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-20-3506

DO - 10.1158/1078-0432.CCR-20-3506

M3 - Article

C2 - 33106290

AN - SCOPUS:85100350763

SN - 1078-0432

VL - 27

SP - 5

EP - 7

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 1

ER -

Checking the hippo in sarcomatoid renal cell carcinoma with immunotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this